European Pharmaceutical Review

JANUARY 2, 2024

The cell and gene therapy market in 2024 [Research from GlobalData predicts] that the top trend in the pharma industry in 2024 will be cell and gene therapy” With research from GlobalData predicting that the top trend in the pharma industry in 2024 will be cell and gene therapy, AstraZeneca’s new acquisition is supporting this outlook.

Manufacturing 98

Manufacturing Marketing Engineering Pharma 98

Pharmaceutical Technology

MAY 10, 2023

According to a consensus forecast from GlobalData’s Pharma Intelligence Centre, Descovy is estimated to yield $1.83 billion in global sales in 2029, while Truvada estimates amount to $30 million. Truvada has since gone generic, with Teva Pharmaceuticals launching the first FDA-approved Truvada generic in October 2020.

Government 105

Government FDA Pharmaceutical Sales 105

Pharmaceutical Technology

APRIL 24, 2023

According to GlobalData’s Pharma Intelligence Centre, a sales consensus forecasts Brukinsa to have global sales of $3.98 billion in 2029, while Calquence is expected to make $5.31 billion in 2029. billion in 2029. Brukinsa was approved by the US Food and Drug Administration (FDA) in CLL in January 2023.

Food and Drug Administration 52

Food and Drug Administration Side effects Sales Food 52

pharmaphorum

DECEMBER 20, 2022

Verona Pharma is looking odds on for a regulatory approval for its chronic obstructive pulmonary disease (COPD) therapy ensifentrine, after chalking up a second positive phase 3 trial. It has already licensed Chinese rights to the drug to Nuance Pharma for $40 million upfront plus up to $179 million in milestones and double-digit royalties.

Pharma 59

Pharma Sales Leads Marketing 59

Pharmaceutical Technology

MAY 23, 2023

According to a consensus forecast from GlobalData’s Pharma Intelligence Centre, Lumakras, also known as sotorasib, has projected sales of $1.47 billion in 2029. In May 2021, Amgen’s Lumakras was approved for use in adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).

Sales 52

Sales Pharma Pharmaceutical Patients 52

Pharmaceutical Technology

MAY 16, 2023

trillion in Q1 2023, according to GlobalData’s pharma intelligence centre companies database. This growth is expected to continue, with a 62% growth in annual consensus sales forecast from 2023 to 2028, fuelled by the company’s semaglutide portfolio, according to GlobalData’s report, ‘Looking ahead to 2023 – the future of pharma’.

Marketing 52

Marketing Sales Pharma Leads 52

pharmaphorum

SEPTEMBER 30, 2022

7,326,708) was challenged by Mylan Pharma, now Viatris, before the US Patent and Trademark Office (USPTO), which ruled in Merck’s favour last year. 8,414,921), which covers the co-formulation of sitagliptin and metformin and is due to expire in 2029. The US patent (No.

Marketing 59

Marketing Sales Competition FDA 59

World of DTC Marketing

AUGUST 7, 2022

What you pay depends on your drug plan, whether your medication is subject to a deductible, the price tier or level it’s assigned by your plan, how much you have already spent on drugs during a given year, where you buy them, and — in the case of brand-name drugs — the whims of the pharma, PBM and insurance companies. Schumer (D-N.Y.)

Insurance 263

Insurance Doctors Government Physicians 263

European Pharmaceutical Review

JANUARY 18, 2024

In the US in 2029 and in Japan in 2031, Belsomra is set to lose market exclusivity. GlobalData anticipated it will launch in the US and 5EU (France, Germany, Italy, Spain, and the UK) markets during the forecast period, Sulayman Patel, MSci, Pharma Analyst at GlobalData noted. “As million in sales by 2032.

Marketing 98

Marketing Sales Pharmacology Pharma 98

Pharmaceutical Technology

APRIL 4, 2023

According to GlobalData’s Pharma Intelligence Centre, Tagrisso is forecasted to have global sales of $8.19 billion in 2029. Tagrisso was approved for use as a first-line treatment for metastatic NSCLC with EGFR mutation in April 2018. GlobalData is the parent company of Pharmaceutical Technology.

Food and Drug Administration 52

Food and Drug Administration Biopharma FDA Pharmaceutical 52

Pharmaceutical Technology

MARCH 27, 2023

Veklury is currently a blockbuster drug, but its revenues are predicted to drop by 2029. It has been approved since 2020 in Japan. Additional approvals of the drug across a greater range of geographies will increase its demand. There are ongoing Phase II/III trials of Veklury in children.

Manufacturing 52

Manufacturing FDA Marketing Pharmaceutical 52

PM360

APRIL 7, 2023

No one has ever described the pharma market access landscape as simple or easy to understand, and the passage of the Inflation Reduction Act (IRA) is not likely to change that. Pharma manufacturers of brands that are selected for negotiation will absolutely want to ‘pull through’ their coveted, newfound formulary position with HCPs.

Marketing 52

Marketing Pharma Manufacturing Healthcare 52

pharmaphorum

NOVEMBER 24, 2022

and 17.6%, respectively, according to J&J’s pharma unit Janssen. Analysts at GlobalData have previously forecast that Spravato will generate global sales of approximately $383 million by 2029, with its potential pegged back by its cost and a requirement for two hours of patient observation after administration.

Sales 52

Sales Patients Competition Marketing 52

Pharmaceutical Technology

FEBRUARY 3, 2023

This market dynamic will likely intensify both if more adalimumab biosimilars receive interchangeability designation and with increased pressure in the US Pharma market due to the Inflation Reduction Act of 2022. Currently, Boehringer Ingelheim’s Cyltezon is the only adalimumab biosimilar that has received interchangeability designation.

Marketing 52

Marketing Sales Patients Management 52

Pharmaceutical Technology

JULY 15, 2022

Most of the US insulin market is controlled by three pharma companies: Sanofi, Eli Lilly, and Novo Nordisk. Type 1 diabetes (T1D) is forecast to affect five million people in the eight major pharmaceutical markets, which are the US, France, Germany, Italy, Spain, UK, Japan, and Canada, by 2029.

Manufacturing 131

Manufacturing Insurance Pharmaceutical Marketing 131

PM360

SEPTEMBER 21, 2023

The product, manufactured by ARS Pharma and Neurelis Pharma, would be the first needle-free epinephrine alternative to autoinjectors, such as the EpiPen. This increases to 15 Part D drugs in 2026, as well as 15 Part B and D drugs in 2028, and a full 20 Part B and D drugs in 2029.

Management 105

Management Manufacturing Sales Competition 105

European Pharmaceutical Review

JUNE 16, 2023

According to Maximize Market Research , new technologies are expected to boost the clinical trials market between 2022 to 2029, especially as the industry and patients are shifting towards digitalisation approaches and personalised medicines.

Safety 111

Safety Electronics Recruitment Patients 111

Pharmaceutical Technology

MARCH 7, 2023

billion by 2029, registering a CAGR of over 8% during the forecast period of 2022-2029. The product flow and dosing requirements of solids vary considerably from one industry to another, for example, product flow characteristics from foods to pharma. Recent analysis valued the market [i] at USD 8.5

Distribution 52

Distribution Safety Management Pharmaceutical 52

Pharmaceutical Technology

MAY 17, 2023

According to consensus forecasts from GlobalData’s Pharma Intelligence Centre, Ocaliva is forecasted to have global sales of $1.08 billion in 2029. This results in bile buildup in the liver and can lead to scarring. The condition gradually worsens and can result in liver failure.

Food and Drug Administration 52

Food and Drug Administration FDA Pharmaceutical Prospecting 52

Clarivate

OCTOBER 17, 2024

A second Trump administration would like face pushback if it abandoned or overturned the drug-pricing reforms of the Inflation Reduction Act, which includes numerous pieces that will prove popular with seniors, even as the industry faces price negotiations on top drugs, long an industry non-starter.

Healthcare 52

Healthcare Healthcare Government Insurance 52